Home › Targets › TACSTD2
Radioligand therapy target profile

TROP2 (TACSTD2): IHC Expression in Cancer and Radioligand Target Profile

tumor associated calcium signal transducer 2 · Ensembl ENSG00000184292 · Data updated 2026-11-01
Also known as: TACSTD2, TROP-2, EGP-1, GA733-1

TROP2 (TACSTD2), tumor associated calcium signal transducer 2, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, TROP2 staining is highest in skin cancer (73% of samples positive), cervical cancer (64% of samples positive) and thyroid cancer (67% of samples positive). Evidence on whether TROP2 internalizes is mixed. Clinical status: FDA-approved drug (any modality).

Is TROP2 the right target for your program? Rank it against 15,000 targets on dosimetry, internalization and clinical risk.

Analyze TROP2 free
LocalizationCell-Surface
Top cancer (IHC)Skin Cancer
InternalizationUncertain
Clinical stageFDA-approved drug (any modality)
Active trialsSee ClinicalTrials.gov
Cancer association (Open Targets)0.63

Is TROP2 a good radioligand therapy target?

Scored against the six criteria that decide whether a protein can become a radioligand therapy:

TROP2 IHC staining by cancer type

Protein expression of TROP2 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.

Cancer typeIHC scoreLevel% positive
Skin Cancer0.39Medium73%
Cervical Cancer0.36Medium64%
Thyroid Cancer0.33Medium67%
Bladder Cancer0.30Medium55%
Lung Cancer0.23Medium50%
Head and Neck Cancer0.17Low50%
Pancreatic Cancer0.12Low27%
Endometrial Cancer0.11Low33%
Colorectal Cancer0.08Low25%
Liver Cancer0.06Low9%
Ovarian Cancer0.06Low8%

Not detected by IHC in: lymphoma, breast cancer, melanoma, kidney cancer, neuroendocrine tumors, prostate cancer, gastric cancer, testicular cancer, glioma.

Is TROP2 internalized?

Uncertain. Insufficient literature found.

TROP2 clinical trials

FDA-approved drug (any modality). Nuclens hasn't indexed trials for TROP2 yet. Search ClinicalTrials.gov for TROP2 trials.

TROP2 normal tissue expression

Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See TROP2 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.

TROP2 gene essentiality (DepMap)

CRISPR knockout effect across 1253 cancer cell lines: -0.09 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.

Related skin cancer radioligand targets

EGFR · c-MET (MET) · HER3 (ERBB3) · SSTR2 · B7-H3 (CD276) · HER2 (ERBB2) · ITGAV · ITGB6

See all radioligand therapy targets in skin cancer.

See how TROP2 ranks against 15,000 targets for your indication.

Analyze TROP2 free

Data sources

Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.

Is TROP2 the right target for your program? · 5 free analyses, no card Analyze TROP2 free